Vaping laws changed in Australia on 1st October 2021, making nicotine-containing vape liquid a Schedule 4 prescription-only medicine.
Applied Cannabis Research welcomes PM Scott Morrison’s announcement of a Royal Commission into suicide among Australia’s veterans and serving Defence personnel. We continue to help
Aruma Labs teams up with Applied Cannabis Research for endometriosis observational study Applied Cannabis Research is pleased to announce Aruma Labs (Aruma) has joined Australia’s
The CMOS is expected to run for five years, with patients to be recruited nationwide via medical centers, prescribing GP’s, and specialists. Earlier today the
Australia’s Largest Medicinal Cannabis Study To Date Applied Cannabis Research, Industry Heavyweights and Nationwide Medical Networks Join Forces For a Study of 20,000 Patients, Applied
Cannabidiol (CBD) basics Cannabidiol (CBD) is one of the two dominant cannabinoids in the cannabis species. Since its discovery in 1940 CBD has been subject
Medicinal cannabis offers flexibility in that it can be administered via a range of administration routes with systemic or targeted actions.
Many Australians with IBD use cannabis for symptom management – but their doctors aren’t convinced Two recently published surveys on inflammatory bowel disease (IBD) and
A new survey published on June 8 2020, the Cannabis as Medicine Survey (CAMS-18), has highlighted that despite legalisation of medicinal cannabis in Australia in
Medicinal Cannabis and Wasting Syndrome: What Can It Do? Cachexia is a condition, also known as ‘wasting syndrome’, characterised by loss of body mass associated
© 2022 All rights reserved, Applied Cannabis Research
